Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

ss and products. These and other risks are discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2006, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of this release, and Myriad undertakes no duty to update this information unless required by law.

Contact:
William A. Hockett
EVP, Corporate Communications
(801) 584-3600
Email Contact





'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference

Post Your Comments:
(Date:11/6/2009)...,, - Trial Will Compare NXL103 With Leading...esistant Staphylococcus Aureus (MRSA) Infections ,...pany focused on the discovery and,development of n...ant global,problem of microbial resistance, announ...l NXL103 (flopristin/linopristin), has started a P...
(Date:11/5/2009)...ea Technologies, Inc., a leading provider of devel...tical products announced the addition of customize...m of services, which will be overseen by the newly...tion Development. This investment in an experience...long with new laboratory facilities and state-of-t...
(Date:11/5/2009)...stCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" ...trial of Topical Interferon Alpha-2b for the treat...ent enrollment, with the required 120th patient ra...d and placebo-controlled Phase II trial is underwa...ents participating in the trial self-administer ac...
Breaking Medicine Technology:Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 5333 1Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 5333 2BMEYE B V Completes EUR 6 Million Series B Financing Round 5329 1BMEYE B V Completes EUR 6 Million Series B Financing Round 5329 2BMEYE B V Completes EUR 6 Million Series B Financing Round 5329 3Advanced Health Media Announces Acquisition of Ephikacy LLC 5324 1Advanced Health Media Announces Acquisition of Ephikacy LLC 5324 2Advanced Health Media Announces Acquisition of Ephikacy LLC 5324 3
...d YONGIN, South Korea, Jan. 12 Jennerex,Inc. (San... Korean partner,Green Cross Corp., today announced... primary liver cancer clinical trial using its tar...xicities were reported, and enrollment of,patients...rial involves treatment of patients with advanced,...
... 12 Cara Therapeutics, Inc. today announced that ...long-acting peripheral kappa opioid agonist, CR845...-controlled trial will be conducted in the United ...d safety of intravenous CR845 during the post-oper...ted hysterectomy. The trial is expected to enroll ...
Other Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain 2
(Date:11/8/2009)...Passage of Health Care Reform Bill ,, Critica...overage for all Americans ,, CHICAGO, Nov. 7 /... House of Representatives passed by a vote of 220-...would strengthen Medicare for seniors and end disc...ions of Americans out of affordable health coverag...
(Date:11/7/2009)...PRNewswire-USNewswire/ -- Karen Ignagni, President...), released the following statement today on House...y support comprehensive health care reform, and we...a complete overhaul of how health insurance is pro...overage, elimination of pre-existing condition exc...
(Date:11/7/2009)...n (CT), David A. Cook (GA), Louis J. Goodman (TX),...d ,, CHICAGO, Nov. 7 /PRNewswire-USNewswire/ -...sented five medical society executive leaders with...o the goals and ideals of the medical profession. ... policy making meeting in Houston. ,, (Logo: ...
(Date:11/7/2009)...atholics have a responsibility to vigorously oppos... quo." ,, WASHINGTON, Nov. 7 /PRNewswire-US... Brown released the following statement on the new... Nancy Pelosi,s Affordable Health Care for America... the status quo for abortion is voted upon. ,,...
(Date:11/7/2009)...lic Relations Society of America (PRSA) will besto...Lofgren, senior vice president of Brand Strategy, ...ht at a ceremony at PRSA,s 2009 International Conf... PRSA College of Fellows is one of the profession,... APR, SAGE, Fellow PRSA, and 2009 chair of the Col...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3
...h Inc. announced today,that it will independently ...ies to outside firms in the pharmaceutical and bio...ue its 23-year collaboration with Pfizer but,will ...d dispersion (SDD) technology,(which increases the...
...y reduces risk of chronic diseases and,can help re...nation, CHICAGO, Oct. 20 Small steps can lead to...lthier Life Steps campaign,launched today. As fami...lthy lifestyle at little or no cost. New,resources...
... less effective, more painful than singular proced...-- Laser therapies to remove unwanted hair may be ...er than in combination, according to an Iranian st...r long-pulsed 755-nanometer alexandrite lasers (12...
...on Plan(TM), Health Management Program to ... U.S. Preventive Medicine(R), the leader,in diseas...fers,Association (AGA Tour), a Lilburn, GA -based .... The Prevention,Plan(TM) is a groundbreaking heal...
...tCall/ - The Westaim Corporation,announced today i...ting,obligations associated with its previous Nasd....S. Securities and Exchange Act of 1934, as,amende...hares will continue to trade on the TSX under the ...
...caling Back Chronic Disease,Initiatives, WASHINGT...sponding to reports that many Americans are forgoi...day called for renewed vigilance,in the fight agai... or carpooling, for example -- we can,t afford to,...
Other Medicine News:Health News:Bend Research Offers Broad Access to Drug-Delivery Solutions 2Health News:AMA Aims to Help Americans Get Healthier One Step at a Time 2Health News:Study Evaluates Laser Therapies for Hair Removal 2Health News:U.S. Preventive Medicine(R) Tees Up with Amateur Golf Association 2Health News:Westaim to deregister its common stock in the United States 2Health News:Nation's Economic Downturn Threatens Continuity of Care for Chronic Conditions 2
27 Gauge Air Injection Cannula
Reverse Double Barreled Irrigation/Aspiration Set
Irrigation/Aspiration Cannula
Infusion Lens Loop
Medicine Products: